Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Can patients with locally advanced rectal cancer safely avoid radiation and its often serious side effects? Pamela Kunz, MD, FASCO breaks down new data from the PROSPECT trial presented at #ASCO23. See the study results

ASCO

151,059 subscribers

18,631 views • 3 years ago •via X (Twitter)

Health & Wellness Science & Technology Education #ASCO23

Anya Rossi• Live Now

Private livecam show

1 Comments

ASCO1 year ago

Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25

Related Videos

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.

Dr. Misheck Ruwende

107,404 views • 3 years ago

Dr. Deb Schrag discusses the controversy regarding a study of a new approach to treating rectal cancer that sidesteps the need for radiation, thereby avoiding long-term side effects and preserving fertility. Listen to the full episode:

Dr. Deb Schrag discusses the controversy regarding a study of a new approach to treating rectal cancer that sidesteps the need for radiation, thereby avoiding long-term side effects and preserving fertility. Listen to the full episode:

NEJM

70,595 views • 3 years ago

Follow along with breast oncologist & ASCO member Stephanie Graff, MD, FACP, FASCO as she takes you through a #DayInTheLife, juggling cancer research, lectures & collaborations, family time, and more! On other days, her time is spent in clinic caring for patients with breast cancer.

Follow along with breast oncologist & ASCO member Stephanie Graff, MD, FACP, FASCO as she takes you through a #DayInTheLife, juggling cancer research, lectures & collaborations, family time, and more! On other days, her time is spent in clinic caring for patients with breast cancer.

ASCO

50,761 views • 2 years ago

Diabetes drugs like Mounjaro and Ozempic, which some patients also use to lose weight, may help patients suffering from addiction, a new study shows. Dr. Céline Gounder, MD, ScM, FIDSA 🇺🇦 breaks down the study — and some of the potential risks of the medications.

Diabetes drugs like Mounjaro and Ozempic, which some patients also use to lose weight, may help patients suffering from addiction, a new study shows. Dr. Céline Gounder, MD, ScM, FIDSA 🇺🇦 breaks down the study — and some of the potential risks of the medications.

CBS Mornings

18,490 views • 1 year ago

Drug companies Moderna and Merck have released encouraging results from a vaccine trial that shows promise in the battle against Stage 3 and Stage 4 melanoma, the most serious type of skin cancer. Dr. Natalie Azar breaks down the findings.

Drug companies Moderna and Merck have released encouraging results from a vaccine trial that shows promise in the battle against Stage 3 and Stage 4 melanoma, the most serious type of skin cancer. Dr. Natalie Azar breaks down the findings.

TODAY

37,988 views • 3 years ago

A brand new drug from $BHVN promises to promote muscle gain in patients taking GLP-1 obesity drugs CEO Vlad Coric breaks down the treatment's latest clinical trial results and how soon it could impact patients and the weight loss space:

CNBC's Fast Money

39,012 views • 2 years ago

The journey of ppl living w cancer is filled with stressful sounds. What if there was a sound that could give them hope? At #ASCO23, discover The Most Beautiful Sound: for the first time, we’ve captured the sound of cancer cells being destroyed. #ASCO_MBS

The journey of ppl living w cancer is filled with stressful sounds. What if there was a sound that could give them hope? At #ASCO23, discover The Most Beautiful Sound: for the first time, we’ve captured the sound of cancer cells being destroyed. #ASCO_MBS

ASCO

15,758 views • 3 years ago

This week we went to DC with ASCO member Sumanta K. Pal, MD, FASCO for the #ASCOAdvocacySummit. Follow his day as he met with fellow ASCO advocates and Members of Congress. You can still take action online:

This week we went to DC with ASCO member Sumanta K. Pal, MD, FASCO for the #ASCOAdvocacySummit. Follow his day as he met with fellow ASCO advocates and Members of Congress. You can still take action online:

ASCO

12,327 views • 1 year ago

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

841,885 views • 25 days ago

Hey, don’t forget to submit that #GI26 abstract! It’s your time to shine and help shape the future of GI cancer care with your #gicsm study in progress or a late-stage clinical trial. Abstracts are due Sept. 9 at 11:59 p.m. (ET). Learn more:

Hey, don’t forget to submit that #GI26 abstract! It’s your time to shine and help shape the future of GI cancer care with your #gicsm study in progress or a late-stage clinical trial. Abstracts are due Sept. 9 at 11:59 p.m. (ET). Learn more:

ASCO

10,199 views • 11 months ago

🚨 SHOCKING BOMBSHELL: They’ve been hiding this from you. Dr. Peter McCullough just exposed it in this video: A new real-world study of 197 cancer patients treated with low-dose Ivermectin (25 mg) + Mebendazole (250 mg). After just 6 months: 84.4% had clinical benefit 48.4% had tumor reduction or no detectable disease 86.9% completed treatment with only mild side effects Patients got scans every 3 months. Dr. McCullough breaks it down: tiny doses, massive results, and almost no downside. This is what the cancer industry and Big Pharma fear most — cheap, repurposed drugs actually working while they push trillion-dollar chemo and endless “treatments.” Cancer isn’t being cured because it’s too profitable.

🚨 SHOCKING BOMBSHELL: They’ve been hiding this from you. Dr. Peter McCullough just exposed it in this video: A new real-world study of 197 cancer patients treated with low-dose Ivermectin (25 mg) + Mebendazole (250 mg). After just 6 months: 84.4% had clinical benefit 48.4% had tumor reduction or no detectable disease 86.9% completed treatment with only mild side effects Patients got scans every 3 months. Dr. McCullough breaks it down: tiny doses, massive results, and almost no downside. This is what the cancer industry and Big Pharma fear most — cheap, repurposed drugs actually working while they push trillion-dollar chemo and endless “treatments.” Cancer isn’t being cured because it’s too profitable.

Dr. Dawn Michael

116,001 views • 1 month ago

As #ASCO23 begins, #ASCOAdvocacy & American Cancer Society Cancer Action Network join OVAC in calling on Congress to prioritize #cancerresearch funding for NIH and National Cancer Institute. Our CEO Clifford Hudis & @AmerCancerCEO discuss why and how to get involved. 🗣️ Add your voice:

As #ASCO23 begins, #ASCOAdvocacy & American Cancer Society Cancer Action Network join OVAC in calling on Congress to prioritize #cancerresearch funding for NIH and National Cancer Institute. Our CEO Clifford Hudis & @AmerCancerCEO discuss why and how to get involved. 🗣️ Add your voice:

ASCO

23,094 views • 3 years ago

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

Dana-Farber

60,054 views • 2 months ago

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study

MJTruthUltra

28,932 views • 6 days ago

Dr. Patrick Soon-Shiong Exposes the Cancer Treatment Lie: "Chemo & Radiation Destroy Your Body’s Best Defense—Here’s the Breakthrough That Actually Works" For decades, the world fought cancer with two brutal weapons: chemotherapy and radiation. But what if these treatments weaken the very system designed to save you? Hidden in your body for 460 million years are natural killer cells—your immune system’s elite soldiers against cancer. Yet chemo, radiation, steroids, and even newer drugs like Temodol cripple these cells. One radiation dose can shut them down for a year—leaving patients defenseless when they need protection most. Now, the game has changed. After battling Big Pharma, FDA roadblocks, and systemic resistance, Dr. Soon-Shiong’s team has pioneered a single-injection "Bio-Shield" therapy that activates your body’s natural cancer-fighting army. The results? ✅ Bladder cancer patients disease-free for 10+ years ✅ No toxic chemo or radiation side effects ✅ Potential to treat long COVID, HIV & sepsis The Biden administration blocked this breakthrough—along with COVID treatments—but the dam has broken. The future of medicine isn’t poisoning the body to save it. It’s unleashing the power God put inside us. The full story drops in Cancer Decoded. Follow to learn how we’re ending the era of suffering—and saving millions.

Dr. Patrick Soon-Shiong Exposes the Cancer Treatment Lie: "Chemo & Radiation Destroy Your Body’s Best Defense—Here’s the Breakthrough That Actually Works" For decades, the world fought cancer with two brutal weapons: chemotherapy and radiation. But what if these treatments weaken the very system designed to save you? Hidden in your body for 460 million years are natural killer cells—your immune system’s elite soldiers against cancer. Yet chemo, radiation, steroids, and even newer drugs like Temodol cripple these cells. One radiation dose can shut them down for a year—leaving patients defenseless when they need protection most. Now, the game has changed. After battling Big Pharma, FDA roadblocks, and systemic resistance, Dr. Soon-Shiong’s team has pioneered a single-injection "Bio-Shield" therapy that activates your body’s natural cancer-fighting army. The results? ✅ Bladder cancer patients disease-free for 10+ years ✅ No toxic chemo or radiation side effects ✅ Potential to treat long COVID, HIV & sepsis The Biden administration blocked this breakthrough—along with COVID treatments—but the dam has broken. The future of medicine isn’t poisoning the body to save it. It’s unleashing the power God put inside us. The full story drops in Cancer Decoded. Follow to learn how we’re ending the era of suffering—and saving millions.

Camus

127,084 views • 1 year ago

Numbers don’t lie—but they can certainly be ignored. Steve Kirsch breaks down the data from the Czech Republic, and the results are eye-opening. If an intervention is successful, we should see a shift in the trend. Instead, the line stayed perfectly straight. Why was this data overlooked?

Numbers don’t lie—but they can certainly be ignored. Steve Kirsch breaks down the data from the Czech Republic, and the results are eye-opening. If an intervention is successful, we should see a shift in the trend. Instead, the line stayed perfectly straight. Why was this data overlooked?

Mary Talley Bowden MD

10,583 views • 4 months ago

Just issued: Guideline update on #palliativecare for patients with cancer. Read more: #pallonc #supponc

Just issued: Guideline update on #palliativecare for patients with cancer. Read more: #pallonc #supponc

ASCO

34,630 views • 2 years ago